信号通路介导乳腺癌内分泌治疗耐药的研究进展(5)
[28] Cristofanilli M，Turner N C，Bondarenko I，et al.Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive，HER2-negative matastatic breast cancer that progressed on previous endocrine therapy(PALOMA-3)：final analysis of the multicentre，double-blind，phase 3 randimised controlled trial[J].Lancet Oncol，2016，17(4)：425-439.
[29] Bian X，Liang Z，Feng A，et al.HHDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL[J].Biochem Pharmacol，2018，147：30-37.
[30] West A C，Johnstone R W.New and emerging HDAC inhibitors for cancer treatment[J].J Clin Invest，2014，124(1)：30-39.
[31] Yardley D A，Iamail-Khan R R，Melichar B，et al.
Randomized phaseⅡ，double-blind，placebo-controller study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatas[J].J Clin Oncol，2013，31：2128-2135.
[32] Trapani D，Esposito A，Criscitiello C，et al.Entinostat for the treatment of breast cancer[J].Expert Opin Investing Drugs，2017，26(8)：965-971.
[33] Zhang X，Zhang B，Liu J，et al.Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression[J].Sci Rep，2015，5：7835.
[34] Cristofanilli M，Valero V，Mangalik A，et al.PhaseⅡ， randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer[J].Clin Cancer Res，2010，16(6)：1904., 百拇医药(范凤凤 郭宇)
[29] Bian X，Liang Z，Feng A，et al.HHDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL[J].Biochem Pharmacol，2018，147：30-37.
[30] West A C，Johnstone R W.New and emerging HDAC inhibitors for cancer treatment[J].J Clin Invest，2014，124(1)：30-39.
[31] Yardley D A，Iamail-Khan R R，Melichar B，et al.
Randomized phaseⅡ，double-blind，placebo-controller study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatas[J].J Clin Oncol，2013，31：2128-2135.
[32] Trapani D，Esposito A，Criscitiello C，et al.Entinostat for the treatment of breast cancer[J].Expert Opin Investing Drugs，2017，26(8)：965-971.
[33] Zhang X，Zhang B，Liu J，et al.Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression[J].Sci Rep，2015，5：7835.
[34] Cristofanilli M，Valero V，Mangalik A，et al.PhaseⅡ， randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer[J].Clin Cancer Res，2010，16(6)：1904., 百拇医药(范凤凤 郭宇)
参见：首页 > 医疗版 > 疾病专题 > 普通外科 > 乳腺癌